StockData
Savara Inc logo

Savara Inc (SVRA) company profile

SVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$5.21+0.49 (+10.38%)

Close on Nov 19, 2026Market cap $1.07BP/E –Yield –

About Savara

Pharmaceutical Preparations, SIC 2834

Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company's sole program is molgramostim inhalation solution, an investigational biologic consisting of inhaled granulocyte-macrophage colony-stimulating factor. It is being developed specifically to treat autoimmune pulmonary alveolar proteinosis, a rare condition that causes surfactant accumulation within the lungs' air sacs. Molgramostim delivers the therapeutic formulation using an exclusive, proprietary nebulizer system, with patients afflicted by this rare autoimmune condition serving as its primary target population.

The company operates without internal commercial manufacturing facilities, relying on third-party contract organizations to supply drug substance, produce drug products, and provide the inhalation delivery devices across clinical testing phases. Savara maintains its principal executive offices in Langhorne, Pennsylvania. Beyond its operations in the United States, the company's activities involve foreign suppliers and research initiatives spanning Europe, the United Kingdom, and Japan.

Summary of the business section of Savara's latest annual report, written by StockData.

Company profile

Company

Legal name
Savara Inc
Headquarters
Austin, TX
Address
6836 Bee Cave Road, Building 3, Suite 201 78746
Phone
51285113796
Employees
70, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
RSM US LLP, Boston, Massachusetts

Stock & identifiers

Ticker
SVRA
Former tickers
MSTX until May 9, 2017
Exchange
Nasdaq
IPO date
Apr 28, 2017
Shares outstanding
205M, Aug 11, 2026
Public float
$544.46M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-70 reverse, May 9, 2017
SEC CIK
1160308
CUSIP
805111101
ISIN
US8051111016
FIGI
BBG000MS0823
Share class FIGI
BBG001SFTVM9
LEI
5493002JO0WM3YMJXG33
EIN
84-1318182

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Matthew PaulsCHIEF EXECUTIVE OFFICER, Director1,188,050
Braden C. ParkerChief Commercial Officer75,677
Robert Matthew LutzChief Fin. & Operating Officer328,977
David L. LowranceChief Financial Officer953,968
Kathleen R. McCabeChief Legal Officer519,232
Anne EricksonChief Business Officer371,712
Yasmine WasfiChief Medical Officer168,008
Raymond Dennis PrattChief Medical Officer340,050
Joseph S. McCrackenDirector302,644
David A. RamsayDirector2,533,642
Richard J. HawkinsDirector161,326
Es-Johansson An vanDirector102,500
Nevan C. ElamDirector106,887

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.85M$9.89M$2.39M$196–
FY2024$4.91M$3.97M$1.87M$65–
FY2023$3.76M$5.66M$2.09M$303–
FY2022$2.20M$2.51M$876.41K$125–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Matthew Pauls
Chief Executive Officer
$660.00K$3.87M–$297.00K$18.00K$4.85M-1%
Yasmine Wasfi
Chief Medical Officer
$476.73K$1.69M$246.74K$186.85K$18.00K$2.62M–
Robert Lutz
Chief Operating Officer
$471.00K$1.61M–$176.63K$18.00K$2.28M+22%
David Lowrance
Chief Financial & Administrative Officer & Secretary
$471.00K$1.61M–$176.63K$18.00K$2.28M+22%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of March 13, 2026, we had approximately 70 employees as well as several third-party consultants.”

Corporate history

Events identified from SEC filings

DateEventDetails
Nov 15, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 15, 2019Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 3, 2019Auditor changeChange in certifying accountant (8-K Item 4.01)
May 30, 2017Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 27, 2017ListingRegistration of securities on an exchange (Form 8-A)
Apr 27, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 27, 2017DelistingNotice of delisting from exchange (Form 25)
Apr 25, 2017Name changeName changed from Mast Therapeutics, Inc. to Savara Inc
Apr 10, 2017Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 10, 2017MergerRegistration of securities for a merger or exchange offer (S-4)
Apr 5, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 1, 2013Name changeName changed from ADVENTRX PHARMACEUTICALS INC to Mast Therapeutics, Inc.
Jun 29, 2011Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 23, 2011Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 11, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 2, 2009Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 1, 2006Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 27, 2004ListingRegistration of securities on an exchange (Form 8-A)
May 15, 2003Name changeName changed from BIOKEYS PHARMACEUTICALS INC to ADVENTRX PHARMACEUTICALS INC
Mar 28, 2003Late filingNotification of late filing
Nov 15, 2002Late filingNotification of late filing
Aug 14, 2002Late filingNotification of late filing
May 15, 2002Late filingNotification of late filing
Apr 1, 2002Late filingNotification of late filing

See a number that looks wrong?